18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Not Recruiting

Trial ID: NCT03824535

Purpose

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Official Title

18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules

Stanford Investigator(s)

Carina Mari Aparici
Carina Mari Aparici

Clinical Professor, Radiology - Rad/Nuclear Medicine

Eligibility

Inclusion Criteria:

* Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
* Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
* Current or former cigarette smoker, with \>= 20 pack years
* Documented informed consent

Exclusion Criteria:

* History or previous diagnosis of lung cancer
* Cancer diagnosis within the last 5 years
* Pregnant or nursing

Intervention(s):

drug: Fludeoxyglucose F-18

drug: Fluorine F 18 L-glutamate Derivative BAY94-9392

diagnostic_test: Computed Tomography

diagnostic_test: Positron Emission Tomography (PET/CT)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mahima Goel
650-723-0371

New Trial Alerts